Prelude Therapeutics Incorporated
$4.47
-$0.05 (-1.11%)
$4.36Day Range$4.65
Key Statistics
Market Cap
$360.71M
Shares Outstanding
79.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 25, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$4.55
Day High
$4.65
Day Low
$4.36
Volume
191.6K
VWAP
$4.45
Prev Close
$4.52
Transactions
--
Acc. Volume
--
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
PHARMACEUTICAL PREPARATIONSSIC 283479 employees175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805(302) 467-1280IPO Sep 25, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001678660
- Composite FIGI
- BBG00K7JY2Q6
- Share Class FIGI
- BBG00K7JY2R5
- Ticker Root
- PRLD
- SIC Code
- 2834
About Prelude Therapeutics Incorporated (PRLD) Stock
Prelude Therapeutics Incorporated (PRLD) closed the 2026-09-16 session at $4.47, down 1.11% versus the previous close (-0.05). The stock opened at $4.55 and traded between $4.36 and $4.65 during that session. Session trading volume was 192K shares. The volume-weighted average price (VWAP) is $4.45.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Prelude Therapeutics Incorporated has a market capitalization of $360.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PRLD is listed on the XNAS exchange. The company employs approximately 79 people. Prelude Therapeutics Incorporated is headquartered in WILMINGTON, DE. The recorded listing date is 2020-09-25.
On this page you can find market PRLD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.